This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-09 and is reviewed periodically as new material appears.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
=== Other === An engineer replaced a woodpecker-damaged feed horn of a high-power microwave antenna, a 15-meter dish at an Earth station of a television network, using a cherry picker. After finishing, he sent his technician to power up the transmitter, and attempted to lower the cherry picker down. The engine failed and the engineer was stuck next to the antenna, outside of its main lobe but well within the first sidelobe. The technician, unaware that the engineer was still close to the antenna, powered it up. The engineer was exposed to an intense microwave field for about three minutes, until the error was realized. There were no immediate symptoms; the next morning the engineer detected blood and solid matter in his urine, and visited a doctor, who found blood in stool and massive bowel adhesions. The engineer's medical problems lasted for many years.
The two were together for eight months between 2015 and 2016. Kardashian began dating basketball player Tristan Thompson in 2016. Kardashian gave birth to a daughter, True Thompson, on April 12, 2018, amidst controversy after Thompson was found to have cheated on Kardashian during her pregnancy. In February 2019, Kardashian and Thompson split after it was revealed that Thompson had allegedly cheated on Kardashian with her younger half-sister Kylie Jenner's then-best friend Jordyn Woods. After quarantining together during the COVID-19 pandemic for the sake of their daughter, they ended up rekindling their relationship in August 2020. They became engaged in February 2021, but split for good in December 2021, when it was revealed that Thompson had cheated on Kardashian again in March 2021, and fathered a son who was born in December 2021. In July 2022, it was announced that Kardashian and Thompson were expecting a baby boy via surrogacy, who was conceived before Kardashian discovered Thompson's cheating. Their son, Tatum, was born on July 28, 2022.
=== Nationalization === After the U.S. entered World War I, due to its German connections, Merck & Co. was the subject of expropriation under the Trading with the Enemy Act of 1917. The government seized 80 percent of the shares owned by the German parent company and sold it. In 1919, George F. Merck (head of the American branch of the Merck family), in partnership with Goldman Sachs and Lehman Brothers, bought the company back at a U.S. government auction for $3.5 million, but Merck & Co. remained a separate company from its former German parent. Merck & Co. holds the trademark rights to the "Merck" name in the United States and Canada, while its former parent company retains the rights in the rest of the world; the right to use the Merck name was the subject of litigation between the two companies in 2016. In 1925, George W. Merck succeeded his father George F. Merck as president. In 1927, the corporation merged with the Powers-Weightman-Rosengarten Company, a Philadelphia quinine manufacturer. George Merck remained president and Frederic Rosengarten became chairman of the board. In 1929, H. K. Mulford Company merged with Sharp and Dohme, Inc. and brought vaccine technology, including immunization of cavalry horses in World War I and delivery of a diphtheria antitoxin to Merck & Co. In 1943, streptomycin was discovered during a Merck-funded research program in Selman Waksman's laboratory at Rutgers University. It became the first effective treatment for tuberculosis.
Sutherland then studied the mechanism and foundthat the increased formation of phosphorylase in liver was mediated by a certain substance, later named cAMP. At the time, this was the only known physiological function of enzymatic phosphorylation, as a physiological control mechanism for one metabolic pathway, until 1969, when it was discovered that mitochondrial pyruvate dehydrogenase complex was inactivated by phosphorylation. Also in the 1970s, the term multisite phosphorylation was coined, to describe the new discovery that some proteins are phosphorylated on two or more residues by two or more kinases. In 1975, it was shown that cAMP-dependent proteins kinases phosphorylate serine residues on specific amino acid sequence motifs. Ray Erikson discovered that v-Src was a kinase and Tony Hunter found that v-Src phosphorylated tyrosine residues on proteins in the 1970s. In the early 1980, the amino-acid sequence of the first protein kinase was determined which helped geneticists understand the functions of regulatory genes. In the late 1980s and early 1990s, the first protein tyrosine phosphatase (PTP1B) was purified and the discovery, as well as, cloning of JAK kinases was accomplished which led to many in the scientific community to name the 1990s as the decade of protein kinase cascades. Edmond Fischer and Edwin Krebs were awarded the Nobel prize in 1992 "for their discoveries concerning reversible protein phosphorylation as a biological regulatory mechanism".
Sources: en.wikipedia.org
Bergamot essential oil has been used in cosmetics, aromatherapy, and as a flavoring in food and beverages. Its citrus scent makes it a natural flavoring and deodorizing agent. The volatile oils of the bergamot orange are described as flavoring agents in the USP Food Chemicals Codex and are generally recognized as safe for human consumption by the US Food and Drug Administration. For example, Earl Grey tea is a type of black tea that may contain bergamot essential oil as a flavoring agent. Historically, bergamot essential oil was an ingredient in Eau de Cologne, a perfume originally concocted by Johann Maria Farina at the beginning of the 18th century. The first record of bergamot oil used as a fragrance in perfume is from 1714, found in the Farina Archive in Cologne.
The cells undergo freeze-drying, the dehydration being the basic cause of freezing injury. The rate of cooling has been shown to influence the frost resistance of tissues, but the actual rate of freezing will depend not only on the cooling rate, but also on the degree of supercooling and the properties of the tissue. Sakai (1979a) demonstrated ice segregation in shoot primordia of Alaskan white and black spruces when cooled slowly to 30 °C to -40 °C. These freeze-dehydrated buds survived immersion in liquid nitrogen when slowly rewarmed. Floral primordia responded similarly. Extraorgan freezing in the primordia accounts for the ability of the hardiest of the boreal conifers to survive winters in regions when air temperatures often fall to -50 °C or lower. The hardiness of the winter buds of such conifers is enhanced by the smallness of the buds, by the evolution of faster translocation of water, and an ability to tolerate intensive freeze dehydration. In boreal species of Picea and Pinus, the frost resistance of 1-year-old seedlings is on a par with mature plants, given similar states of dormancy.
== Pharmacology == Itopride acts as a selective dual D2 receptor antagonist and acetylcholinesterase inhibitor. There is evidence that itopride may have prokinetic effects throughout the gastrointestinal tract from the stomach to the end of the colon. The pharmacokinetics of itopride appear to differ between Asian and Caucasian populations, with Caucasians having 30-50 percent lower blood levels of itopride after oral administration. Itopride poorly penetrates across the blood brain barrier because of its high polarity and thus itopride does not tend to cause any central nervous system adverse effects. Itopride has no effect on potassium channels. Similarly to other D2 receptor antagonists, itopride has been found to dose-dependently increase prolactin levels.
The Single Cell resource presents comprehensive data on gene expression across various human tissues and cell types, utilizing single cell RNA sequencing (scRNAseq), cell sorting, single nuclei RNA sequencing (snRNAseq), Deep Visual Proteomics (based on mass spectrometry), and bulk RNAseq correlation analyses. The resource provides insights into mRNA and protein expression patterns, gene specificity, and expression clustering with single cell types, immune cells and brain single nuclei. The Single Cell Resource includes five main datasets: - The Single cell type section, providing the expression profiles across 154 cell types from 34 human tissues, and cell type specificity based on gene expression. - The Deep Visual Proteomics section, providing protein detection in 27 cell types from 14 tissue types - The Tissue cell type section, providing the predicted cell-type expression specificity based on bulk RNAseq - The Single nuclei brain section, providing more details regarding cell type specificity within the brain, based on single nuclei RNAseq - The Immune cell section, providing expression comparison between sorted immune cells The Cancer resource is based on mRNA expression data from 21 cancer types as well as protein data from 20 cancers analyzed by IHC and 11 cancer types analyzed using MS. This data is displayed together with millions of in-house generated immunohistochemically stained tissue sections images and Kaplan-Meier plots showing the correlation between mRNA expression of each human protein gene and cancer patient survival.
Estrogen also causes the laying down of fat in the development of the secondary sex characteristics. This contributes to the maturation of the vulva with increases in the size of the mons pubis, and the labia majora and the enlargement of the labia minora.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.